Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KPI-012 in persistent corneal epithelial defect
NCT05727878Phase 2Terminated
- Sponsor
- Combangio, Inc.
- Start
- Feb 2023
- Primary completion
- Sep 2025
- Modality
- Lipid-based Nanoparticles, Recombinant Proteins and Enzymes, Stem Cell Therapies
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of KPI-012 in persistent corneal epithelial defect (PED) (4 cohorts), sponsored by Combangio, Inc. Primary endpoint: Response Status at 56 days. Started Feb 2023; status: terminated.
02
Drugs
KPI-012
03
Conditions
persistent corneal epithelial defect (PED)
Beyond the preview
Go deeper on NCT05727878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05727878.